{"success":true,"data":{"pressRelease":{"id":"168868","rtpr_id":"nPn1KvLz5a-20261014","ticker":"SCNI","exchange":"NASDAQ","all_tickers":["SCNI","2F50Y"],"title":"Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement","author":"PR Newswire","published_at":"2026-10-14T12:00:21.809Z","article_body":"Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement\nPR Newswire\n\nJERUSALEM, October 14, 2026\n\nJERUSALEM, October 14, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.\n(https://www.scinai.com/) (NASDAQ: SCNI) (\"Scinai\" or the \"Company\"), a\nbiopharmaceutical company operating a growing contract development and\nmanufacturing organization (\"CDMO\") alongside an immunology-focused\ntherapeutic development platform, today announced that it has entered into a\nsecurities purchase agreement with an existing life sciences institutional\ninvestor for the purchase and sale of 2,458,334 American Depositary Shares\n(\"ADSs\") (or pre-funded warrants in lieu thereof), each ADS representing\n40,000 ordinary shares, together with Series A-1 warrants to purchase up to\n3,687,501 ADSs, at an exercise price of $1.20 per ADS, exercisable immediately\nwith a term of five years, at a combined purchase price of $1.20 per ADS and\naccompanying warrants (or $1.1999 per pre-funded warrant and accompanying\nwarrants). Each pre-funded warrant will have a remaining exercise price of\n$0.0001 per ADS.\n\nIn addition, the Company entered into a warrant inducement agreement with the\nsame investor for the immediate cash exercise of warrants issued in April 2026\nto purchase an aggregate of 879,194 ADSs (the \"Existing Warrants\") at a\nreduced exercise price of $1.20 per ADS.\n\nIn consideration for the immediate exercise in full of the Existing Warrants\nfor cash, the investor will receive in a private placement new unregistered\nSeries A-1 warrants to purchase up to 1,318,791 ADSs (the \"New Warrants\"). The\nNew Warrants will have an exercise price of $1.20 per ADS, will be exercisable\nimmediately, and will expire five (5) years from the date of issuance.\n\nThe aggregate gross proceeds from the private placement and the warrant\ninducement transaction are expected to be approximately $4.0 million, before\ndeducting placement agent fees and expenses. These proceeds exclude any future\nproceeds from the exercise of the newly issued Series A-1 warrants. The\nclosing of the transactions is expected to occur on or about October 15, 2026,\nsubject to satisfaction of customary closing conditions.\n\nScinai intends to use the net proceeds, together with existing cash resources,\nto support the expansion of its CDMO platform, advance customer programs, and\ncontinue selective investment in its immunotherapy pipeline. The Company\nbelieves this financing will support the execution of its growth strategy.\n\nA.G.P./Alliance Global Partners is acting as the sole placement agent for the\ntransactions.\n\nThe ADSs issuable upon exercise of the Existing Warrants have been registered\nfor resale pursuant to the Company's effective registration statement on Form\nF-3 (File No. 333-295698). The ADSs and warrants offered in the private\nplacement, the New Warrants and the securities underlying those warrants have\nnot been registered under the Securities Act of 1933, as amended (the\n\"Securities Act\"), or applicable state securities laws. The offer and sale of\nthe securities in the private placement and the New Warrants will be made in\nreliance on an exemption from registration under Section 4(a)(2) of the\nSecurities Act and Regulation D promulgated thereunder. Accordingly, these\nunregistered securities may not be offered or sold in the United States except\npursuant to an effective registration statement or an applicable exemption\nfrom the registration requirements of the Securities Act and such applicable\nstate securities laws. The Company has agreed to file a registration statement\nwith the SEC to register for resale the ADSs issued in the private placement,\nthe ADSs issuable upon exercise of the pre-funded warrants and New Warrants,\nand the underlying ordinary shares.\n\nThis press release does not constitute an offer to sell or a solicitation of\nan offer to buy any of the securities described herein, nor shall there be any\nsale of these securities in any state or other jurisdiction in which such\noffer, solicitation or sale would be unlawful prior to the registration or\nqualification under the securities laws of any such state or other\njurisdiction.\n\nAbout Scinai Immunotherapeutics\n\nScinai Immunotherapeutics Ltd. (https://www.scinai.com/) (Nasdaq: SCNI) is a\nbiopharmaceutical company operating a growing contract development and\nmanufacturing organization alongside an immunology-focused therapeutic\ndevelopment platform.\n\nThrough its wholly owned subsidiary, Scinai Biopharma Services Ltd.\n(https://www.scinai.com/cdmo) , the Company provides development and\nmanufacturing services to biotechnology and pharmaceutical companies at its\nfacilities in Jerusalem and Yavne, Israel. Scinai also advances its NanoAb\nplatform through research collaboration and license arrangements with the Max\nPlanck Society and University Medical Center Göttingen, both in Germany.\n\nFor more information, please visit: www.scinai.com (http://www.scinai.com/)\n\nCompany Contacts\n\nBusiness Development | +972 8 930 2529 | bd@scinai.com (mailto:bd@scinai.com)\n\nInvestor Relations, Allele Capital Partners | Brian DeBeer | +1 (561) 388-8178\n| Brian.DeBeer@scinai.com (mailto:Brian.DeBeer@scinai.com)\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements under applicable U.S.\nsecurities laws, including the Private Securities Litigation Reform Act of\n1995. Forward-looking statements include, among other things, statements\nregarding the timing and completion of the private placement and warrant\ninducement, the expected gross proceeds, the anticipated use of proceeds and\nthe expected benefits of the financing.\n\nActual outcomes may differ materially from current expectations. Relevant\nrisks include the risk that one or both transactions may not close on the\nanticipated terms or timetable, or at all; technical, analytical,\nmanufacturing, quality or regulatory difficulties; delays in equipment,\nmaterials or third-party services which can lead to delays in payments;\nchanges in customer requirements or development plans; contractual\nmodification or termination; delayed payments; failure to meet milestones; and\ndifferences between anticipated billings, cash collections and recognized\nrevenue. Additional risks include financing requirements, market conditions,\ncompetition, geopolitical conditions and the other risks described in the\nCompany's Annual Report on Form 20-F and subsequent filings with the U.S.\nSecurities and Exchange Commission.\n\nForward-looking statements reflect expectations as of the date of this\nrelease. Scinai undertakes no obligation to update them except as required by\nlaw.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/scinai-immunotherapeutics-announces-4-0-million-financing-through-a-private-placement-and-warrant-inducement-302908431.html\n(https://www.prnewswire.com/news-releases/scinai-immunotherapeutics-announces-4-0-million-financing-through-a-private-placement-and-warrant-inducement-302908431.html)\n\nSOURCE Scinai Immunotherapeutics Ltd.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1069511/Scinai-Immunotherapeutics-Logo.jpg?id=OA3018319\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn1KvLz5a-20261014","title":"Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement","author":"PR Newswire","ticker":"SCNI","created":"2026-10-14T12:00:21.809Z","tickers":["SCNI","2F50Y"],"exchange":"NASDAQ","article_body":"Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement\nPR Newswire\n\nJERUSALEM, October 14, 2026\n\nJERUSALEM, October 14, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.\n(https://www.scinai.com/) (NASDAQ: SCNI) (\"Scinai\" or the \"Company\"), a\nbiopharmaceutical company operating a growing contract development and\nmanufacturing organization (\"CDMO\") alongside an immunology-focused\ntherapeutic development platform, today announced that it has entered into a\nsecurities purchase agreement with an existing life sciences institutional\ninvestor for the purchase and sale of 2,458,334 American Depositary Shares\n(\"ADSs\") (or pre-funded warrants in lieu thereof), each ADS representing\n40,000 ordinary shares, together with Series A-1 warrants to purchase up to\n3,687,501 ADSs, at an exercise price of $1.20 per ADS, exercisable immediately\nwith a term of five years, at a combined purchase price of $1.20 per ADS and\naccompanying warrants (or $1.1999 per pre-funded warrant and accompanying\nwarrants). Each pre-funded warrant will have a remaining exercise price of\n$0.0001 per ADS.\n\nIn addition, the Company entered into a warrant inducement agreement with the\nsame investor for the immediate cash exercise of warrants issued in April 2026\nto purchase an aggregate of 879,194 ADSs (the \"Existing Warrants\") at a\nreduced exercise price of $1.20 per ADS.\n\nIn consideration for the immediate exercise in full of the Existing Warrants\nfor cash, the investor will receive in a private placement new unregistered\nSeries A-1 warrants to purchase up to 1,318,791 ADSs (the \"New Warrants\"). The\nNew Warrants will have an exercise price of $1.20 per ADS, will be exercisable\nimmediately, and will expire five (5) years from the date of issuance.\n\nThe aggregate gross proceeds from the private placement and the warrant\ninducement transaction are expected to be approximately $4.0 million, before\ndeducting placement agent fees and expenses. These proceeds exclude any future\nproceeds from the exercise of the newly issued Series A-1 warrants. The\nclosing of the transactions is expected to occur on or about October 15, 2026,\nsubject to satisfaction of customary closing conditions.\n\nScinai intends to use the net proceeds, together with existing cash resources,\nto support the expansion of its CDMO platform, advance customer programs, and\ncontinue selective investment in its immunotherapy pipeline. The Company\nbelieves this financing will support the execution of its growth strategy.\n\nA.G.P./Alliance Global Partners is acting as the sole placement agent for the\ntransactions.\n\nThe ADSs issuable upon exercise of the Existing Warrants have been registered\nfor resale pursuant to the Company's effective registration statement on Form\nF-3 (File No. 333-295698). The ADSs and warrants offered in the private\nplacement, the New Warrants and the securities underlying those warrants have\nnot been registered under the Securities Act of 1933, as amended (the\n\"Securities Act\"), or applicable state securities laws. The offer and sale of\nthe securities in the private placement and the New Warrants will be made in\nreliance on an exemption from registration under Section 4(a)(2) of the\nSecurities Act and Regulation D promulgated thereunder. Accordingly, these\nunregistered securities may not be offered or sold in the United States except\npursuant to an effective registration statement or an applicable exemption\nfrom the registration requirements of the Securities Act and such applicable\nstate securities laws. The Company has agreed to file a registration statement\nwith the SEC to register for resale the ADSs issued in the private placement,\nthe ADSs issuable upon exercise of the pre-funded warrants and New Warrants,\nand the underlying ordinary shares.\n\nThis press release does not constitute an offer to sell or a solicitation of\nan offer to buy any of the securities described herein, nor shall there be any\nsale of these securities in any state or other jurisdiction in which such\noffer, solicitation or sale would be unlawful prior to the registration or\nqualification under the securities laws of any such state or other\njurisdiction.\n\nAbout Scinai Immunotherapeutics\n\nScinai Immunotherapeutics Ltd. (https://www.scinai.com/) (Nasdaq: SCNI) is a\nbiopharmaceutical company operating a growing contract development and\nmanufacturing organization alongside an immunology-focused therapeutic\ndevelopment platform.\n\nThrough its wholly owned subsidiary, Scinai Biopharma Services Ltd.\n(https://www.scinai.com/cdmo) , the Company provides development and\nmanufacturing services to biotechnology and pharmaceutical companies at its\nfacilities in Jerusalem and Yavne, Israel. Scinai also advances its NanoAb\nplatform through research collaboration and license arrangements with the Max\nPlanck Society and University Medical Center Göttingen, both in Germany.\n\nFor more information, please visit: www.scinai.com (http://www.scinai.com/)\n\nCompany Contacts\n\nBusiness Development | +972 8 930 2529 | bd@scinai.com (mailto:bd@scinai.com)\n\nInvestor Relations, Allele Capital Partners | Brian DeBeer | +1 (561) 388-8178\n| Brian.DeBeer@scinai.com (mailto:Brian.DeBeer@scinai.com)\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements under applicable U.S.\nsecurities laws, including the Private Securities Litigation Reform Act of\n1995. Forward-looking statements include, among other things, statements\nregarding the timing and completion of the private placement and warrant\ninducement, the expected gross proceeds, the anticipated use of proceeds and\nthe expected benefits of the financing.\n\nActual outcomes may differ materially from current expectations. Relevant\nrisks include the risk that one or both transactions may not close on the\nanticipated terms or timetable, or at all; technical, analytical,\nmanufacturing, quality or regulatory difficulties; delays in equipment,\nmaterials or third-party services which can lead to delays in payments;\nchanges in customer requirements or development plans; contractual\nmodification or termination; delayed payments; failure to meet milestones; and\ndifferences between anticipated billings, cash collections and recognized\nrevenue. Additional risks include financing requirements, market conditions,\ncompetition, geopolitical conditions and the other risks described in the\nCompany's Annual Report on Form 20-F and subsequent filings with the U.S.\nSecurities and Exchange Commission.\n\nForward-looking statements reflect expectations as of the date of this\nrelease. Scinai undertakes no obligation to update them except as required by\nlaw.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/scinai-immunotherapeutics-announces-4-0-million-financing-through-a-private-placement-and-warrant-inducement-302908431.html\n(https://www.prnewswire.com/news-releases/scinai-immunotherapeutics-announces-4-0-million-financing-through-a-private-placement-and-warrant-inducement-302908431.html)\n\nSOURCE Scinai Immunotherapeutics Ltd.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1069511/Scinai-Immunotherapeutics-Logo.jpg?id=OA3018319\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-14T12:00:21.858754107Z","server_sent_at_ms":1791979221858},"received_at":"2026-10-14T12:00:21.909Z","source_url":"https://www.prnewswire.com/news-releases/scinai-immunotherapeutics-announces-4-0-million-financing-through-a-private-placement-and-warrant-inducement-302908431.html"},"analysis":{"id":"157119","press_release_id":"168868","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["April 2026 warrants re-priced downward to $1.20 to induce exercise — investor extracting concessions","~5.0 million warrant ADSs issued/exercisable vs 2.46M ADSs sold — heavy dilution overhang","unregistered securities requiring future resale registration","small $4.0M raise suggests limited cash runway"],"eventType":"offering","narrative":"Scinai Immunotherapeutics announced a $4.0 million financing combining a private placement of 2,458,334 ADSs with Series A-1 warrants and a warrant inducement at $1.20 per ADS.\n\nAn existing life sciences institutional investor will immediately exercise April 2026 warrants on 879,194 ADSs at the reduced $1.20 price in exchange for new five-year warrants on up to 1,318,791 additional ADSs.\n\nProceeds will fund CDMO expansion, customer programs, and selective pipeline investment; A.G.P./Alliance Global Partners is sole placement agent. The warrant repricing and roughly 5 million new warrant ADSs create meaningful dilution overhang for this micro-cap.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Micro-cap biotech buys near-term cash at the cost of warrant repricing and a large dilution overhang."},"keyFigures":{"dealValueUsd":4000000,"offeringPrice":1.2,"sharesOffered":"2,458,334 ADSs plus Series A-1 warrants on up to 3,687,501 ADSs and 1,318,791 ADSs (New Warrants); Existing Warrants on 879,194 ADSs exercised","customDimensions":{"warrant_term":"5 years","new_warrant_ads":1318791,"warrant_exercise_price":"$1.20 per ADS","existing_warrants_exercised_ads":879194}},"quotedText":"the investor will receive in a private placement new unregistered Series A-1 warrants to purchase up to 1,318,791 ADSs","namedEntities":{"people":[{"name":"Brian DeBeer","role":"Investor Relations, Allele Capital Partners"}],"products":["NanoAb platform"],"companies":[{"name":"Scinai Immunotherapeutics Ltd.","ticker":"SCNI","relationship":"filer"},{"name":"A.G.P./Alliance Global Partners","relationship":"placement agent"},{"name":"Allele Capital Partners","relationship":"investor relations"},{"name":"Max Planck Society","relationship":"research collaboration partner"},{"name":"University Medical Center Göttingen","relationship":"research collaboration partner"}],"dollarAmounts":[{"amount":"$4.0 million","context":"aggregate gross proceeds from private placement and warrant inducement"},{"amount":"$1.20 per ADS","context":"combined purchase price and warrant exercise price"},{"amount":"$0.0001","context":"remaining exercise price of pre-funded warrants"}]},"materialImpact":{"score":3,"reasoning":"A $4.0M private placement plus a warrant inducement that re-prices April 2026 warrants down to $1.20, with heavy new warrants (~5M ADSs) creating substantial dilution for a small-cap. Financing is meaningful but modest in absolute size."},"tickerRelevance":{"others":[],"primary":"SCNI"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"small dilutive financing with warrant inducement","issuerAuthored":true}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"bearish","material_impact_score":3,"narrative":"Scinai Immunotherapeutics announced a $4.0 million financing combining a private placement of 2,458,334 ADSs with Series A-1 warrants and a warrant inducement at $1.20 per ADS.\n\nAn existing life sciences institutional investor will immediately exercise April 2026 warrants on 879,194 ADSs at the reduced $1.20 price in exchange for new five-year warrants on up to 1,318,791 additional ADSs.\n\nProceeds will fund CDMO expansion, customer programs, and selective pipeline investment; A.G.P./Alliance Global Partners is sole placement agent. The warrant repricing and roughly 5 million new warrant ADSs create meaningful dilution overhang for this micro-cap.","key_figures":{"dealValueUsd":4000000,"offeringPrice":1.2,"sharesOffered":"2,458,334 ADSs plus Series A-1 warrants on up to 3,687,501 ADSs and 1,318,791 ADSs (New Warrants); Existing Warrants on 879,194 ADSs exercised","customDimensions":{"warrant_term":"5 years","new_warrant_ads":1318791,"warrant_exercise_price":"$1.20 per ADS","existing_warrants_exercised_ads":879194}},"named_entities":{"people":[{"name":"Brian DeBeer","role":"Investor Relations, Allele Capital Partners"}],"products":["NanoAb platform"],"companies":[{"name":"Scinai Immunotherapeutics Ltd.","ticker":"SCNI","relationship":"filer"},{"name":"A.G.P./Alliance Global Partners","relationship":"placement agent"},{"name":"Allele Capital Partners","relationship":"investor relations"},{"name":"Max Planck Society","relationship":"research collaboration partner"},{"name":"University Medical Center Göttingen","relationship":"research collaboration partner"}],"dollarAmounts":[{"amount":"$4.0 million","context":"aggregate gross proceeds from private placement and warrant inducement"},{"amount":"$1.20 per ADS","context":"combined purchase price and warrant exercise price"},{"amount":"$0.0001","context":"remaining exercise price of pre-funded warrants"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-14T12:00:41.737Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"small dilutive financing with warrant inducement","issuerAuthored":true}},"durationMs":6496,"modelName":"glm-5.3-flashx"}}